Clinical Trial Protocol for Digestive Enzyme Supplementation in Gastrectomy Patients
The PANEM trial is a randomized, phase III, parallel-arm, placebo-controlled, double-blind study designed to assess the impact of pancreatic enzyme supplementation on the quality of life (QOL) of patients following partial or total gastrectomy. Patients who undergo these surgeries often experience malnourishment and a diminished quality of life due to altered digestive processes. The trial will involve 188 participants who will be randomly assigned to receive either the digestive enzyme NORTASE® or a placebo for six months. The primary outcome will be the cancer-specific QOL measured by the EORTC-QLQ-C30 physical sub-score after six months. Secondary outcomes will include additional QOL measures, weight loss, and laboratory assessments related to malnutrition and metabolism. This study is significant as it addresses a gap in research regarding the effectiveness of digestive enzymes in this patient population, where previous studies have yielded inconsistent results. The trial is set to take place across multiple centers in Germany and is sponsored by Leipzig University with funding from Repha GmbH Biologische Arzneimittel. The ethical approval for the study has been obtained, and it adheres to stringent clinical trial regulations. Participants will be informed about the trial during their hospital stay, and informed consent will be required before enrollment. The findings from this trial could provide valuable insights into improving the nutritional management of patients post-gastrectomy, potentially enhancing their overall well-being and quality of life.




